EP
SLDB icon

Eversept Partners’s Solid Biosciences SLDB Stock Holding History

Eversept Partners’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,468
Closed -$623K – 69
2020
Q3 		$623K Sell
20,468
-6,667
-25% -$255K 0.14% 44
2020
Q2 		$1.19M Buy
+27,135
New +$1.13M 0.16% 59

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Eversept Partners's SLDB Position: Q4 2020 in Review

Eversept Partners sold out of Solid Biosciences (SLDB) in Q4 2020, closing a stake of 20,468 shares — an estimated $623K sold.

Eversept Partners first reported a position in SLDB in Q2 2020 and held it in 2 quarters. The position peaked at $1.19M in Q2 2020. 75 funds tracked by Wall St. Rank hold SLDB as of Q4 2020.

  • Eversept Partners reported no remaining Solid Biosciences position as of Q4 2020 after selling out during the quarter.
  • Eversept Partners sold 20,468 Solid Biosciences shares in Q4 2020, an estimated $623K.
  • Eversept Partners first reported a position in Solid Biosciences in Q2 2020 and held it in 2 quarters.
  • Eversept Partners's Solid Biosciences position peaked at $1.19M in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2020.

Based on Eversept Partners's 13F filing for Q4 2020, filed 16 Feb 2021.